Zydus Cadila awaits product approvals worth US $6 billion
With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business
With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business
The company is expecting tremendous growth and a better quarterly performance
Viruses evolve into new strains when there is a change to their genetic composition.
Subscribe To Our Newsletter & Stay Updated